LncRNA microarray profiling identifies novel circulating lncRNAs in hidradenitis suppurativa.


Journal

Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 17 05 2023
accepted: 13 02 2024
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 17 5 2024
Statut: ppublish

Résumé

Long noncoding RNAs (lncRNAs) have been demonstrated to be involved in biological processes, both physiological and pathological, including cancer, cardiovascular diseases, multiple sclerosis, autoimmune hepatitis and types I and II diabetes. LncRNAs are also known to have a critical role in the physiology of skin, and in the pathology of cutaneous diseases. LncRNAs are involved in a wide range of biological activities, including transcriptional post‑transcriptional processes, epigenetics, RNA splicing, gene activation and or silencing, modifications and/or editing; therefore, lncRNAs may be useful as potential targets for disease treatment. Hidradenitis suppurativa (HS), also termed acne inversa, is a major skin disease, being an inflammatory disorder that affects ~1% of global population in a chronic manner. Its pathogenesis, however, is only partly understood, although immune dysregulation is known to have an important role. To investigate the biological relevance of lncRNAs with HS, the most differentially expressed lncRNAs and mRNAs were first compared. Furthermore, the lncRNA‑microRNA regulatory network was also defined via reverse transcription‑quantitative PCR analysis, whereby a trio of lncRNA expression signatures, lncRNA‑TINCR, lncRNA‑RBM5‑ASI1 and lncRNA‑MRPL23‑AS1, were found to be significantly overexpressed in patients with HS compared with healthy controls. In conclusion, the three lncRNAs isolated in the present study may be useful for improving the prognostic prediction of HS, as well as contributing towards an improved understanding of the underlying pathogenic mechanisms, thereby potentially providing new therapeutic targets.

Identifiants

pubmed: 38757342
doi: 10.3892/mmr.2024.13236
pii: 112
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Bruna De Felice (B)

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania Luigi Vanvitelli, I-81100 Caserta, Italy.

Pasquale De Luca (P)

Anton Dohrn Naples Zoological Station, I-80121 Naples, Italy.

Concetta Montanino (C)

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania Luigi Vanvitelli, I-81100 Caserta, Italy.

Marta Mallardo (M)

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania Luigi Vanvitelli, I-81100 Caserta, Italy.

Graziella Babino (G)

Dermatology Unit, University of Campania Luigi Vanvitelli, I-80131 Naples, Italy.

Edi Mattera (E)

Department of Internal and Experimental Medicine and Surgery Unit of Internal Medicine, University of Campania Luigi Vanvitelli, I-80131 Naples, Italy.

Raffaele Sorbo (R)

Department of Internal and Experimental Medicine and Surgery Unit of Internal Medicine, University of Campania Luigi Vanvitelli, I-80131 Naples, Italy.

Giovanni Ragozzino (G)

Department of Internal and Experimental Medicine and Surgery Unit of Internal Medicine, University of Campania Luigi Vanvitelli, I-80131 Naples, Italy.

Giuseppe Argenziano (G)

Dermatology Unit, University of Campania Luigi Vanvitelli, I-80131 Naples, Italy.

Aurora Daniele (A)

CEINGE‑Franco Salvatore Advanced Biotechnology, I-80145 Naples, Italy.

Ersilia Nigro (E)

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania Luigi Vanvitelli, I-81100 Caserta, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH